US2013110025A1PendingUtilityA1
Dressing device for use wtih a cannula or a catheter
Est. expiryJul 14, 2030(~3.9 yrs left)· nominal 20-yr term from priority
A61L 2300/404A61L 2400/04A61L 2300/45A61F 13/00063A61L 2300/206A61L 2300/418A61L 2300/232A61L 15/46A61L 15/26
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A wound dressing device for use with a transcutaneous medical device such as a cannula or a catheter comprises a polyurethane matrix which may be covered with a film backing. Chlorhexidine di- gluconate and a polyanhydroglucuronic salt are contained in the polymer matrix. The wound dressing device prevents microbial colonization of the dressing and stops bleeding from the insertion site. The device provides combined haemostatic and antimicrobial effects at the insertion site but without adversely affecting wound healing.
Claims
exact text as granted — not AI-modified1 . A dressing device for use with a transcutaneous medical device such as a cannula or a catheter, the dressing device comprising a flexible hydrophillic polyurethane matrix, an antimicrobial agent contained within the matrix, and a haemostatic agent contained within the matrix, the haemostatic agent comprising polyanhydroglucuronic acid or salt thereof in an amount to achieve a haemostatic effect, and the antimicrobial agent comprising chlorhexidine di-gluconate in an amount to achieve an antimicrobial effect without adversely affecting wound healing.
2 . The dressing device as claimed in claim 1 wherein the polyanhydroglucuronic salt is present in an amount of from 3% to 20% (w/w).
3 . The dressing device as claimed in claim 1 wherein the polyanhydroglucuronic salt is present in an amount of approximately 8% (w/w).
4 . The dressing device as claimed in claim 1 wherein the chlorhexidine di-gluconate is present in an amount of from 9% to 16% (w/w).
5 . The dressing device as claimed in claim 1 wherein the chlorhexidine di-gluconate is present in an amount of approximately 11% (w/w).
6 . The dressing device as claimed claim 1 any comprising approximately 8% (w/w) polyanhydroglucoronic acid, approximately 11% (w/w) chlorhexidine di-gluconate, and approximately 81% hydrophillic flexible polyurethane foam.
7 . The dressing device as claimed in claim 1 comprising an aperture for reception of a medical device such as a cannula or a catheter.
8 . The dressing device as claimed in claim 1 comprising a breathable backing material to allow vapour transmission from the device.
9 . The dressing as claimed in claim 1 wherein a skin contacting side of the device contains an adhesive to retain the device affixed to a site.
10 . The wound dressing device as claimed in claim 7 wherein the central access aperture is a circular hole ranging in size from 0.1 mm to 10 mm in diameter
11 . The wound dressing device as claimed in claim 7 wherein the central access aperture is “x” shaped
12 . The wound dressing device as claimed in claim 7 wherein the central access aperture is “T” shaped.
13 . The wound dressing device as claimed in claim 1 wherein the device contains a quantity of the antimicrobial agent to maintain antimicrobial efficiency for up to 7 days.
14 . The use of a wound dressing as claimed in claim 1 in conjunction with a transcutaneous medical device such as a cannula or a catheter.Join the waitlist — get patent alerts
Track US2013110025A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.